- Home
- SEVN vs COYA Comparison
SEVN vs COYA Comparison
Compare SEVN & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$8.69
HOLD
Current Price
$5.99
Company Overview
Basic Information| Metric | SEVN | COYA |
|---|---|---|
| Founded | 1986 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.0M | 126.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | SEVN | COYA |
|---|---|---|
| Price | $8.69 | $5.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $13.50 | ★ $15.80 |
| AVG Volume (30 Days) | 159.8K | ★ 163.7K |
| Earning Date | 10-27-2025 | 11-12-2025 |
| Dividend Yield | ★ 12.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $29,408,000.00 | $3,987,706.00 |
| Revenue This Year | N/A | $88.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.62 | $4.65 |
| 52 Week High | $13.97 | $8.29 |
Technical Indicators
Market Signals| Indicator | SEVN | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 32.86 | 47.73 |
| Support Level | $8.66 | $5.91 |
| Resistance Level | $8.77 | $6.62 |
| Average True Range (ATR) | 0.11 | 0.33 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 37.25 | 34.04 |
Price Performance
Historical Comparison SEVN
COYA
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.